Inhibitors of Covid protease (3CLpro) for treatment of SARS-CoV-2

Back to all technologies
Download as PDF
2021-GHOS-69510
Purdue University researchers have developed a series of compounds that potently inhibit an enzyme, 3-chymotrypsin like protease (3CLpro), of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The COVID-19 respiratory illness is caused by the SARS-CoV-2 coronavirus strain. While there are currently COVID-19 therapeutics authorized for emergency use, issues remain with efficacy, ease of administration and Covid recurrence. Purdue researchers created a new class of compounds capable of potently inhibiting 3CLpro, the main protease found in SARS-CoV-2 required for efficient viral replication. The Purdue compounds are chemically distinct from the current FDA approved SARS-CoV-2 3CLpro inhibitors and they showed more potent inhibition of 3CLpro and overall antiviral activity compared to the approved compounds.

Technology Validation: These compounds are more potent than an in-house prepared FDA approved compound in an enzymatic kinetics assay.

Advantages:
-More potent in vitro than commercially available compounds
-Distinct chemical architecture from other 3CLpro inhibitors.

Applications:
-COVID-19 treatment
-Antiviral therapy
May 26, 2022
Utility-Gov. Funding
United States
(None)
(None)

May 28, 2021
Provisional-Gov. Funding
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org